363 related articles for article (PubMed ID: 26706662)
1. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
2. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
3. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
[TBL] [Abstract][Full Text] [Related]
4. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
5. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
6. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
Dolapcioglu K; Boz A; Baloglu A
Clin Exp Obstet Gynecol; 2013; 40(1):122-6. PubMed ID: 23724525
[TBL] [Abstract][Full Text] [Related]
9. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
[TBL] [Abstract][Full Text] [Related]
10. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
Zhou H; Cao D; Yang J; Shen K; Lang J
Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
[TBL] [Abstract][Full Text] [Related]
12. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.
Ciccone MA; Whitman SA; Conturie CL; Brown N; Dancz CE; Özel B; Matsuo K
Arch Gynecol Obstet; 2019 Mar; 299(3):801-808. PubMed ID: 30706187
[TBL] [Abstract][Full Text] [Related]
14. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
[TBL] [Abstract][Full Text] [Related]
15. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
16. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
Park JY; Seong SJ; Kim TJ; Kim JW; Bae DS; Nam JH
Gynecol Oncol; 2017 Jul; 146(1):39-43. PubMed ID: 28526167
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
18. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
19. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
[TBL] [Abstract][Full Text] [Related]
20. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
